Clinical trial · Interventional
Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients.
Phase II Prospective Study to Assess Rate for Prolonged Remission With Intensive Chemotherapy in Rapid Respondents AML Patients Younger Than 61 as Demonstrated by Day 5 Examination of the First Treatment.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We previously reported results of a prospective observational study demonstrating that early response defined as reduction in bone marrow (BM) blast counts to less than 5% of BM cells by the fifth day of induction therapy is a strong predictor of remission and overall survival (Ofran Y, et al. AJH, 2015). The long term survival benefit of early response was confirmed later on after a median follow-up for surviving patients of 53 months (range 17.5-84.5).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prescribing conventional chemotherapy while with holding allo-SCT | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- No allogeneic SCT
- description
- For standard or intermediate risk AML patients who achieved good rapid response, allogenic SCT will be excluded from treatment plan
- interventionNames
- Procedure: Prescribing conventional chemotherapy while with holding allo-SCT
- type
- ACTIVE_COMPARATOR
- label
- Standard post induction therapy
- description
- For slow responding AML patients, post induction therapy will be provided according to treating physician discretion
- interventionNames
- Procedure: Prescribing conventional chemotherapy while with holding allo-SCT
Primary outcomes (1)
- measure
- Event free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 61 Years
Show eligibility criteria text
Inclusion Criteria: * AML diagnosis, * treated with 3+7 Induction chemotherapy * Intermediate/standard risk AML Exclusion Criteria: * Diagnosed of APL * high risk molecular/cytogenetic score
References
Publications (0)
Data not yet available